The authors regret that the numbers of bone metastasis in this LEO trial (Table 1) need to be corrected as follows:
Table 1Patient characteristics.
| Characteristics | EVE arm (n = 92) | LET arm (n = 45) |
|---|---|---|
| Age, years, median (range) | 44 (24–54) | 45 (25–56) |
| ECOG performance status | ||
| 0 | 49 (53.3) | 22 (48.9) |
| 1 | 42 (45.7) | 23 (51.1) |
| 2 | 1 (1.1) | 0 |
| Visceral disease | 56 (60.9) | 27 (60.0) |
| Bone only disease | 5 (5.4) | 6 (13.3) |
| Previous sensitivity to endocrine therapy (%) | 68 (73.9) | 34 (75.6) |
| Previous endocrine therapy | ||
| Tamoxifen | 54 (58.7) | 26 (57.8) |
| Tamoxifen → GnRH agonist | 18 (19.6) | 9 (20.2) |
| Tamoxifen + GnRH agonist | 20 (21.7) | 10 (22.2) |
| Previous chemotherapy | 15 (16.3) | 6 (13.3) |
| Measurable disease | 83 (90.2) | 39 (86.7) |
| Number of metastatic sites | ||
| 1 | 26 (28.3) | 15 (33.3) |
| 2 | 29 (31.5) | 14 (31.1) |
| ≥3 | 37 (40.2) | 16 (35.6) |
| Site of metastasis | ||
| Lung | 29 (31.5) | 18 (40.0) |
| Liver | 25 (27.2) | 12 (26.7) |
| Bone | 66 (71.7) | 32 (71.1) |
| Purpose of the most recent treatment | ||
| Adjuvant therapy | 45 (48.9) | 26 (57.8) |
| Palliative therapy | 47 (51.1) | 19 (42.2) |
| Line of treatment | ||
| 1st line | 45 (48.9) | 26 (57.8) |
| 2nd line | 31 (33.7) | 13 (28.9) |
| ≥3rd line | 16 (17.4) | 6 (13.3) |
EVE, everolimus; LET, letrozole; LEUP, leuprorelin; ECOG, Eastern Cooperative Oncology Group; GnRH, gonadotropin-releasing hormone.
∗ Endocrine therapy is considered sensitive if outside of primary endocrine resistance.
Bone meta 59 (64.1)--> 66 (71.7)in the EVE arm.
27 (60.0)--> 31 (71.1) in the LET arm.
Please find the correct Table 1 below. These corrections do not affect any description in the published article.
The authors would like to apologise for any inconvenience caused.
Article info
Publication history
Published online: March 07, 2021
Identification
Copyright
© 2021 Elsevier Ltd. All rights reserved.
